CPC A61K 31/166 (2013.01) [A61K 9/0053 (2013.01); A61P 25/00 (2018.01); A61P 35/00 (2018.01)] | 24 Claims |
1. A method of administering mirdametinib to a human patient in need thereof comprising orally administering mirdametinib to the patient, wherein the patient suffers from a tumor or cancer, and wherein
(a) for a patient having a body surface area no more than 0.69 m2, the patient is initially administered 1 mg mirdametinib twice daily,
(b) for a patient having a body surface area of 0.7 to 1.04 m2, the patient is initially administered 2 mg mirdametinib twice daily,
(c) for a patient having a body surface area of 1.05 to 1.49 m2, the patient is initially administered 3 mg mirdametinib twice daily, and
(d) for a patient having a body surface area of at least 1.5 m2, the patient is initially administered 4 mg mirdametinib twice daily.
|